Asthma patients who continue to experience symptoms despite taking regular inhaled corticosteroids represent a management challenge. Leukotrienes play a key role in asthma pathophysiology, and since pro-in¯ammatory leukotrienes are poorly suppressed by corticosteroids it seems rational to add a leukotriene receptor antagonist (LTRA) when a low to moderate dose of inhaled corticosteroids does not provide sucient disease control. Long acting 2 -agonist (LABA) treatment represents an alternative to LTRAs and both treatment modalities have been shown to provide additional disease control when added to corticosteroid treatment. To compare the relative clinical bene®ts of adding either a LTRA or a LABA to asthma patients inadequately controlled by inhaled corticosteroids, a randomized, double-blind, multi-centre, 48-week study will be initiated at approximately 120 centres throughout Europe, Latin America, Middle East, Africa and the Asia±Paci®c region in early 2000. The study will compare the oral LTRA montelukast with the inhaled LABA salmeterol, each administered on a background of inhaled¯uticasone, on asthma attacks, quality of life, lung function, eosinophil levels, healthcare utilization, and safety, in approximately 1200 adult asthmatic patients. The requirements for study enrolment include a history of asthma, FEV 1 or PEFR values between 50% and 90% of the predicted value together with !12% improvement in FEV 1 after -agonist administration, a minimum pre-determined level of asthma symptoms and daily -agonist medication. The study will include a 4-week run-in period, during which patients previously taking inhaled corticosteroids are switched to open-label¯uticasone (200 "g daily), followed by a 48-week doubleblind, treatment period in which patients continuing to experience abnormal pulmonary function and daytime symptoms are randomized to receive montelukast (10 mg once daily) and salmeterol placebo, or inhaled salmeterol (100 "g daily) and montelukast placebo. All patients will continue with inhaled¯uticasone (200 "g daily). During the study, asthma attacks, overnight asthma symptoms, and morning peak expiratory¯ow rate will be assessed using patient diary cards; quality of life will also be assessed using an asthma-speci®c quality-of life questionnaire. The results of this study are expected to provide physicians with important clinical evidence to help them make a rational and logical treatment choice for asthmatic patients experiencing breakthrough symptoms on inhaled corticosteroids.
Introduction
National and international guidelines recommend inhaled corticosteroids (ICS) as ®rst line therapy for patients with moderate to severe persistent asthma (1±3). However, although ICS improve lung function, symptoms, and reduce asthma exacerbations (4±8), many asthma patients receiving these agents continue to experience symptoms presumably due to underlying in¯ammation. Pro-in¯am-matory leukotriene levels are poorly suppressed by corticosteroids (9) and since these patients are already taking ICS, it is possible that there is a leukotriene-driven component of in¯ammation in these patients.
Currently, there are two approaches to treat asthma patients who continue to experience symptoms on ICS: increase the dose of ICS or add a second therapeutic agent such as an inhaled long-acting -agonist (LABA) or oral leukotriene receptor antagonist (LTRA). Clinical evidence to support the use of increased doses of ICS is variable, with several studies reporting inconsistent eects of higher steroid doses on control of asthma symptoms (10±13). In addition, higher doses of ICS may be associated with sideeects such as adrenal suppression, growth retardation in children, osteoporosis, cataracts, skin thinning and easy bruising (14±16).
Recent studies have suggested that addition of LABAs to ICS are more eective in improving asthma symptoms and lung function than increasing the dose of ICS (17±20). However, concerns have been raised since chronic treatment with LABA results in development of tolerance (21±26), even in those patient treated with ICS (27±29). Another potential concern is the risk of masking underlying airway in¯ammation, thereby allowing an exacerbation of asthma to go unrecognized (30).
Montelukast, a cysteinyl leukotriene receptor antagonist, represents an alternative therapeutic option for patients who continue to experience symptoms on ICS. The antiasthmatic eect is well documented and today there are data from more then 5000 patients (over 2 years of age) treated in clinical trials. World-wide more than 2 million patients have been treated. Montelukast, with or without co-administration of corticosteroids, has been shown to reduce asthma exacerbations and attacks in adults and children (31±34). Moreover, regular treatment with montelukast does not seem to induce tolerance (35,36).
The exact role of leukotrienes in asthma in¯ammation is not known. Leukotrienes increase mucus production and reduce mucociliary clearance (37). They facilitate adhesion and chemotaxis by in¯ammatory cells, especially eosinophils (14, 38) . They also act directly on bronchial smooth muscle cells causing contraction, and stimulate myo®bro-blasts to dierentiate and to form subepithelial ®brosis. Eects on in¯ammatory cells carrying the CysLT 1 receptor may also aect other in¯ammatory cells in an indirect way, for example, by altering cytokine expression and release.
Montelukast has been shown to have signi®cant eects on parameters of asthmatic in¯ammation by blocking the action of leukotrienes, key mediators of airway in¯amma-tion not inhibited by steroids (9,39±41). Studies in children and adults demonstrate montelukast decreases eosinophil counts in peripheral blood, sputum and lung tissue, and reduces exhaled nitric oxide (NO) levels, a non-invasive marker of airway in¯ammation in asthmatics (31±33, 42,43,93). Further, montelukast in combination with beclomethasone dipropionate has recently been shown to produce additive reductions in peripheral blood eosinophils and exacerbations compared with either agent administered individually (44). Treatment with a LTRA has the potential bene®t of both preventing bronchoconstriction, acting as a bronchodilator (45) and having anti-in¯ammatory activity. The bronchodilator eect is smaller than that seen after 2 -agonist treatment. However when LTRAs are added to a 2 -agonist additional eects have been noted (46). This ®nding suggests that montelukast and ICS may oer dierent, yet complementary, anti-in¯ammatory eects in asthma patients incompletely controlled on ICS alone.
To determine whether the addition of a LTRA has an advantage over the addition of a LABA for patients inadequately controlled by ICS alone, we have initiated a controlled clinical trial to compare the relative clinical bene®ts of montelukast and salmeterol, administered on a background of inhaled¯uticasone propionate, on asthma attacks, quality of life, eosinophil levels, healthcare utilization and safety. Beginning in early 2000, this randomized, double-blind, multi-centre clinical trial will involve approximately 1200 adult asthmatic patients not suciently controlled by ICS. The purpose of this report is to summarize the background, rationale and design of this unique comparative study, which is expected to have important clinical rami®cations for the successful management of asthma in the new millennium.
Study design
This is a randomized, double-blind, double-dummy, parallel-group, multi-centre study ranging over 48-weeks after an initial 4-week run-in period. The study has been designed and powered to compare the ecacy and safety of montelukast and salmeterol, when added to ICS therapy (¯uticasone propionate), in preventing asthma attacks in adult asthmatic patients. The study involves approximately 1200 male or female patients aged 15±65 years with persistent asthma. Enrolment will begin in early 2000 at *120 asthma centres throughout Europe, Latin America, Middle East, Africa, and the Asia±Paci®c regions, and the study is expected to take approximately 24 months to complete.
The requirements for study enrolment include a history of asthma, FEV 1 values between 50% and 90% of the predicted value [age 15±17, Hsu (47), age !18, Crapo (48)] together with !12% improvement in FEV 1 or PEFR after -agonist administration, a minimum pre-determined level of daytime and night-time inhaled short-acting -agonist use, and a minimum asthma symptom score. All female patients are required to have a negative urine pregnancy test at screening. Patients will be excluded if they have had emergency treatment for asthma within 1 month of the ®rst visit, hospitalization for asthma within 3 months, unresolved upper respiratory tract infection within 3 weeks, or an active sinus infection.
Study objectives
The primary objective is to compare the eect of montelukast with salmeterol, administered concomitantly with inhaled¯uticasone propionate, on the percentage of patients experiencing at least one asthma attack. For the purpose of this study, an asthma attack is de®ned as treatment with a course of oral corticosteroids or an unscheduled visit to the doctor's oce, emergency room, or hospitalization. An indication for systemic steroid treatment is based upon either objective criterion as increase in symptoms or lung function deterioration, or according to judgement by the responsible investigator. The patients are instructed to contact the doctor if PEFR is 30% below baseline on three consecutive mornings (or 5200 l min 71 ), or if symptoms increase with need for frequent 2 -agonist use (interval less than 3 h). Secondary objectives of the study include peripheral blood eosinophil counts, asthma-speci®c quality of life, nocturnal awakenings, healthcare resource utilization and morning PEFR. In addition, the study will compare the tolerability pro®le of montelukast and salmeterol in combination with inhaled uticasone.
Treatment and follow-up
The study will begin with an initial 4-week run-in period (Period I, Fig. 1 ). During this phase, patients taking ICS, but with abnormal pulmonary function and daytime symptoms, will be placed on open-label¯uticasone propionate (200 "g daily via Discus 1 dry powder inhaler). During the last 2 weeks of Period I, patients will also receive, in a single-blind manner, salmeterol placebo metered dose inhaler (MDI) and montelukast placebo tablets.
The initial run-in period will be followed by a 48-week, double-blind treatment period (Period II). At the beginning of Period II, patients who continue to be inadequately controlled (based on FEV 1 , peak¯ow, -agonist use and daytime symptoms) will be randomized to receive either active montelukast (10 mg once daily) or salmeterol (100 "g daily) in addition to¯uticasone propionate 200 "g daily. All patients will be instructed to take their study tablet once daily at bedtime, with or without food, and to inhale one pu of the¯uticasone pMDI twice daily and two pus from the salmeterol or placebo pMDIs twice daily; in the morning upon arising and at bedtime. Patients will be allowed to (consistently) use a spacer device if desired. Patients will also be carefully instructed to use their inhaled short-acting -agonist on an as needed basis and to avoid habitual use in the absence of symptoms. Both groups will receive montelukast or placebo tablets and salmeterol or placebo pMDIs in a double blind, double-dummy manner, so that patients, study site sta and sponsor sta will be blinded with respect to treatment allocation.
Patients will record asthma attacks, overnight asthma symptoms, and peak expiratory¯ow rate on diary cards. Overnight asthma symptoms will be assessed by the following question: did you wake up with asthma? Patients return the diary cards at clinic visits scheduled at approximately 8-week intervals for the 48 weeks of Period II. The study co-ordinators at each study site will be responsible for reviewing the diary cards for completeness and accuracy with the patient. Patients will be contacted frequently (at least every month) during the 48-week study to ensure accurate and complete recordings on the diary card.
The quality of life of asthma patients will be assessed during the study at weeks 0, 16, 32 and 48 using a validated Asthma-Speci®c Quality-of Life Questionnaire, available in a number of languages (49). This self-administered questionnaire consists of a series of questions pertaining to four asthma-speci®c quality of life domains (activity, symptoms, environment and emotions).
Safety
Safety and tolerability will be monitored throughout the study. Investigators will evaluate clinical adverse experiences in terms of intensity (mild, moderate or severe), duration, seriousness, outcome and relationship to test drugs.
Statistical considerations
To determine how many patients were required for the comparison of montelukast/¯uticasone to salmeterol/¯uti-casone, a sample size estimate was performed based on estimates of the percentage of patients with asthma attacks derived from a previous beclomethasone/montelukast study (44) and the FACET trial (17) . With 480 patients per group, the trial will have at least 80% power to statistically demonstrate that the risk of experiencing at least one asthma attack with montelukast/¯uticasone is less than 1Á33 times the same risk with salmeterol/¯uticasone.
The primary ecacy analysis will be based on the intention-to-treat principle, although a per-protocol analysis will also be performed, taking into account missing data points and clinically important protocol deviations. Comparability of baseline characteristics between the treatment groups will be evaluated with respect to age, gender, race, disease history including disease duration, weight and height. The ratio of the percentage of patients with asthma attacks in the montelukast/salmeterol groups will be calculated using a generalized linear model with binomial distribution and logarithmic link. The treatment eect will be summarized by the risk ratio and its 95% con®dence interval, calculated by the pro®le likelihood method. The montelukast/¯uticasone combination will be considered statistically superior to the salmeterol/¯uticasone combination if the upper limit of the two-sided con®dence interval is less than 1Á0. If the upper limit is less than 1Á33, the montelukast/¯uticasone combination will be considered non-inferior to the salmeterol/¯uticasone combination. If the lower limit is more than 1Á33, the montelukast/ uticasone combination will be considered statistically inferior to the salmeterol/¯uticasone combination. As a secondary analysis, the number of asthma attacks will be analysed by Poisson regression using robust variance estimates (via GEE option in PROC GENMOD).
Organizational structure
At each study site, the principal investigator will be responsible for the care of enrolled patients and the accurate collection of clinical data, particularly in relation to the occurrence of asthma-related events. Specially trained clinical monitors will provide support to the principal investigators and collect data during the trial. A Steering Committee will have overall scienti®c responsibility for the study and for reports generated from study data. This committee will meet periodically to ensure that all procedures are standardized at study sites. Merck Research Laboratories in collaboration with the Steering Committee will process data. 
Discussion
Physicians are frequently faced with the challenge of selecting a safe and eective therapeutic option to manage asthma patients who continue to experience symptoms while taking ICS. Currently, the therapeutic approaches to manage these patients include either increasing the dose of ICS or the addition of a second therapeutic agent, such as an inhaled LABA (e.g. salmeterol), a chromone (e.g. cromolyn and nedocromil), theophylline, or an oral LTRA. However, there have been few comparative studies on the relative ecacy and safety of these therapeutic options in this clinical setting, forcing practitioners to make management decisions based on anecdotal evidence, personal clinical experience, or extrapolation of clinical data from other studies. To help physicians in their decision to select the most eective and safest therapeutic approach for asthmatic patients uncontrolled on ICS alone, we have designed the present study to compare, in a controlled, randomized, double-blind manner, the eects of adding montelukast or salmeterol to a background of inhaled uticasone on asthma attacks, quality of life, eosinophil levels, lung function and healthcare utilization.
Traditionally, surrogate markers of asthma control such as FEV 1 and peak expiratory¯ow rate have assessed eectiveness of preventative therapies for asthma control. However, there is a lack of clinical data validating the relationship between these surrogate endpoints and clinical outcomes such as prevention of asthma attacks. Salmeterol can be expected to have a slightly better bronchodilating potential than montelukast (50). However, recent experiences from the FACET study clearly shows that lung function may not be directly related to the risk of developing asthma attacks. Although the combination of low dose budesonide and formoterol gave the better lung function, increasing the steroid dose was superior in decreasing the numbers of severe exacerbations (17) .
The ability of anti-asthmatic therapies to prevent asthma attacks is important from the perspective of decreasing morbidity and mortality, improving the quality of life of asthma patients, and diminishing the economic costs of the disease by reducing the need for emergency room visits and hospitalizations. For this reason, the percent of patients with at least one asthma attack, de®ned as worsening asthma requiring unscheduled doctor visits, hospitalization, or use of oral corticosteroids, was chosen as the primary endpoint in the present study.
A 10-mg dose of montelukast (once daily at bedtime) was selected for this study on the basis of previous dose-ranging studies (34,51). These studies, which used bedtime dosing to achieve peak plasma drug concentrations in the early morning when asthma characteristically worsens, demonstrated that montelukast 10 mg represents an optimal dose for improving asthma endpoints in chronic asthma patients; higher dosages have not been shown to provide further bene®ts. Further, this dose has been shown to achieve maximal inhibition of exercise-induced bronchoconstriction (52). Salmeterol xinafoate 50 "g twice daily was selected for this study in accordance with the manufacturers prescribing instructions. This dose produces clinically signi®cant bronchodilator eects up to 12 h after a 50 "g dose in asthmatic patients. A study duration of 48 weeks was chosen to re¯ect the fact that asthma is a more or less persistent in¯ammatory disorder of the airways and to ensure that an adequate number of events occurred for a valid statistical comparison between study groups.
It is now well accepted that chronic in¯ammation of the airways, involving in®ltration of multiple in¯ammatory cells such as mast cells, antigen-presenting cells such as dendritic cells, and macrophages, eosinophils, neutrophils and lymphocytes, represents a major pathogenic component of asthma (53). These in¯ammatory cells are responsible for elaborating a broad array of mediators and cytokines in the bronchial epithelium that ultimately give rise to the clinical hallmarks of asthma (14) . Leukotrienes, in particular, represent important mediators of the in¯ammatory process, producing bronchoconstriction, mucosal secretion, cellular in®ltration and increased vascular permeability (38,54±57).
Recognition of the fundamental in¯ammatory nature of asthma has resulted in a shift in the focus of asthma therapy from reliance on bronchodilators to emphasis on antiin¯ammatory agents (53). According to the Global Strategy for Asthma Management and Prevention (3), anti-in¯am-matory agents, particularly ICS, are currently the most eective long-term preventative medications for persistent asthma. However, while ICS eectively improve lung function and symptom control, and decrease asthma exacerbation's (4,6±8,17), many patients receiving ICS continue to experience symptoms. Although low dosages of ICS are generally considered safe, increased dosages of ICS are associated with a variety of potential side-eects, including adrenal suppression, growth retardation in children, osteoporosis, cataracts, skin thinning, and easy bruising (14, 15, 16, 58, 59) . Further, although ICS produce broad inhibition of pathways contributing to airway in¯ammation (53), these agents fail to block the production of cysteinyl leukotrienes that appear to play an important role in the pathophysiology of asthma (9, 41) .
Recent studies in adult asthmatics have shown that addition of the LABA salmeterol to existing ICS therapy (beclomethasone) is more eective in controlling asthma than increasing the dose of ICS (18±20). In addition, asthma patients receiving a combination of LABA (formoterol) and ICS showed a reduced rate of asthma exacerbations (17) . Not all studies, however, have reported more eective asthma control when salmeterol is added to ICS therapy. For example, a recent long-term study in children with moderate asthma reported no additional bene®t of adding salmeterol or increasing the daily dose of beclomethasone (60) . Further, a recent review of LABA in children suggests they are eective bronchodilators and bronchoprotective agents when used as single doses, but not when used chronically (92) .
Both salmeterol and formoterol are designed for use as maintenance treatment and to achieve maximal clinical bene®t, these agents should be taken regularly rather than on an as-needed basis (61) . Concerns have been raised that chronic treatment with 2 -agonists is associated with a deterioration in asthma control, lung function and airway hyperresponsiveness in some patients (62, 63) . Development of tolerance to the protective eect of 2 -agonists on bronchoconstrictor stimuli (e.g. exercise, metacholine or allergen) has been reported in multiple studies (21, 22, 24, 25, 27) , although the bronchodilating eect of these agents appear to be unaected during chronic administration (64, 65) . For example, in a study of the eects of salmeterol on hyperresponsiveness in patients with mild asthma, Cheung et al. reported that regular treatment with salmeterol led to tolerance of its protective eects against the bronchoconstrictor stimulus metacholine, despite well-maintained bronchodilation (22) . Further, the development of tolerance to -agonists appears to be unaected by co-administration of inhaled corticosteroids (27±29,66). This ®nding suggests that asthma patients may experience short-term bronchodilation with -agonists but they may be susceptible to episodes of acute bronchoconstriction induced by newly encountered provocative stimuli (67) . However, recent studies indicate that regular treatment with long-acting 2 -agonist may not be associated with increased risk for worsening of disease control (68) , even in those steroid-naive patients treated with salmeterol only (69) .
It has been proposed that tolerance development by 2 -agonist treatment also should be associated with a decreased ability to control the underlying asthmatic in¯ammation. Thus, the bronchodilation and the symptom-relieving eects of long-acting 2 -agonist treatment may mask a progressive worsening in¯ammation of the airways in asthma patients, thereby potentially delaying awareness of an exacerbation of asthma (30, 70) . Whether the lack of eect on in¯ammatory cells and markers will translate into sub-optimal outcomes is not yet clear (71±76). There are con¯icting data on the interactive eect between 2 -agonist and steroid treatment. One report suggests that -agonists in general, at high doses, may interfere with the anti-asthma eects of inhaled steroids, possibly leading to steroid resistance (77) . However, other in vitro studies indicate that 2 -agonist treatment, conversely, may enhance the eect by steroids through activation of the glucocorticoid receptor (78) . Interestingly a recent report suggests formoterol may decrease tissue eosinophils under some conditions (79) .
Administration of theophylline, cromolyn, or nedocromil is also a potential therapeutic option to manage asthmatic patients who remain symptomatic on ICS. Theophylline is inexpensive compared to both LTRAs and LABAs and has proved to be eective at a low dose combined with ICS treatment (80) . However, theophylline is no longer commonly used as ®rst-line therapy primarily because of modest clinical bene®t, a narrow therapeutic window, need to monitor drug levels, reports of serious adverse reactions, and the potential for drug interactions with commonly used medications (81±83). Cromolyn and nedocromil represent mild to moderate anti-in¯ammatory medications that may be used as initial choice for long-term control therapy (84) . However, there are, as yet, no convincing long-term, controlled studies demonstrating that administration of either in combination with ICS is helpful in managing asthma patients. For example, a study by Toogood et al.
found that adding cromolyn to an established ICS regimen failed to produce a discernible steroid-sparing eect or other clinical advantage (85) .
Montelukast represents an alternative therapeutic option for asthma patients who continue to experience symptoms on ICS. Montelukast provides protection against exerciseinduced bronchoconstriction for up to 20±24 h after dosing (52,86). These protective eects are maintained for a period of at least 12 weeks (35). The absence of tolerance with montelukast after long-term therapy contrasts with that seen with other therapies, including the short-acting inhaled -agonist albuterol, the LABA salmeterol, and the ICS beclomethasone, where reduced eects have been reported to develop after 1 week, 4 weeks and 3 months of therapy, respectively (21, 24, 87, 88, 92) . In a direct, double-blind, randomized comparative study of montelukast and salmeterol in 197 asthmatic men and women aged 15±45 years, montelukast was shown to provide signi®cantly greater inhibition of exercise-induced bronchoconstriction than salmeterol (36). Maintenance of a bronchoprotective eect during long-term therapy is particularly important since it has been estimated that between 40 and 90% of asthmatic patients may be susceptible to developing exercise-induced symptoms (89, 90) .
Asthma is often characterized by the presence of activated eosinophils in the lower airways, and when present, they have been reported to impact the chronicity and severity of asthma (39,91). There is now growing evidence to indicate that the cysteinyl leukotrienes play an important role in the migration of eosinophils into the airways (38,39). By blocking the actions of leukotrienes, montelukast has been shown to have signi®cant eects on parameters of asthmatic in¯ammation, including decreases in eosinophil counts in peripheral blood, sputum, and lung tissue, in both children and adults (14,31±33,42,93) . In a recent 16-week, double-blind, randomized study, montelukast once daily was shown to reduce peripheral blood eosinophil counts to a similar extent as inhaled beclomethasone, and to provide additional control when the two agents were combined (44). Although the precise mechanism of the anti-in¯ammatory properties of montelukast in asthma is still under investigation, recent studies suggest that montelukast may decrease the release of endothelin-1 during eosinophilic airway in¯ammation, as well as inhibit the expression of IL-5 RNA and secretion of cysteinyl leukotrienes by mononuclear cells (40).
Since optimal control of in¯ammation is critical in managing chronic asthma, the addition of montelukast as a second anti-in¯ammatory agent to ICS may represent a logical therapeutic option. The combination of these two agents oers dierent yet additive, anti-in¯ammatory eects since montelukast attenuates the eects of cysteinyl leukotrienes, important pro-in¯ammatory mediators not inhibited by inhaled steroids (9, 41) . In this regard, the present randomized, double-blind study has been designed to determine whether two anti-in¯ammatory agents has an advantage over a bronchodilator and an anti-in¯ammatory agent for asthma patients inadequately controlled by ICS. It is anticipated that the results of this important study will provide physicians with new clinical evidence to help them make a rational and logical treatment choice for asthmatic patients experiencing breakthrough symptoms on ICS. 
